EloraZama is Zama Biosciences’ designation for eloralintide (research code LY3841136), a long-acting selective amylin receptor agonist developed by Eli Lilly. Molecular formula C201H319N49O65S2, molecular weight approximately 4526.1 g/mol.
Research context
Eloralintide binds the human amylin receptors AMY1R and AMY3R with high selectivity over the calcitonin receptor. That selectivity is the defining feature and the reason the compound is of research interest.
Amylin receptors are heterodimers — the calcitonin receptor paired with a receptor activity-modifying protein. Because the calcitonin receptor forms the core of the complex, achieving selectivity for amylin receptors over calcitonin receptors is a non-trivial pharmacological problem. Compounds that engage both produce confounded results in any study isolating amylin signalling.
Published work examines eloralintide in appetite regulation, food intake and body-weight and fat-mass endpoints in research models.
For comparison across this class, cagrilintide is an amylin analogue that also engages calcitonin receptors — the contrast between selective and dual engagement is often the experimental question. Researchers working across metabolic pathways may also want TirZama and RetZama on the incretin side.
This is a recent compound and the literature is correspondingly thin — expect preclinical and early-stage data rather than an established evidence base.
For a fuller treatment of the sequence, published models and technical data, see the eloralintide research guide.
Specification
CAS number 2883634-40-8. Supplied as a lyophilized powder. 99%+ purity verified by HPLC and LC-MS. Available in 5mg and 10mg presentations.
Handling
Reconstitute with bacteriostatic or sterile water, introducing the diluent against the vial wall and swirling gently rather than shaking. As with amylin-class peptides generally, avoid vortexing — mechanical agitation promotes aggregation in this family and fibril formation is not reversible.
Store lyophilized at −20°C protected from light; refrigerate at 2–8°C once reconstituted and inspect for cloudiness before use.
Ships with a batch-specific Certificate of Analysis. Cross-check the batch ID printed on your vial against the CoA before use — see the guide to reading a CoA if you are unfamiliar with the format.
Frequently asked questions about eloralintide
What does selective amylin receptor agonism mean?
Amylin receptors are not standalone proteins. They are heterodimers formed when the calcitonin receptor pairs with a receptor activity-modifying protein — so the calcitonin receptor sits at the core of the amylin receptor itself. Building a compound that activates the amylin complex without also activating bare calcitonin receptors is therefore genuinely difficult, and that selectivity is what defines eloralintide as a research tool.
Eloralintide or cagrilintide?
Cagrilintide engages both amylin and calcitonin receptors and has the larger literature. Eloralintide is selective for amylin receptors. For studies isolating amylin signalling, dual engagement is a confound and the selective compound is the cleaner tool — but cagrilintide remains the better-characterised option where an established comparator matters more than selectivity.
How much published data exists on eloralintide?
Comparatively little. This is a recent compound and the available literature is preclinical and early-stage rather than an established evidence base. Researchers should expect to be working closer to the frontier than with compounds like semaglutide or tirzepatide, where decades of data exist. That is the trade-off for access to a novel selective agonist.
How should eloralintide be handled?
As with amylin-class peptides generally, treat aggregation as the main risk. Reconstitute with bacteriostatic or sterile water, introducing the diluent slowly against the vial wall and swirling — never shake or vortex. Store lyophilized at −20°C protected from light; refrigerate at 2–8°C once reconstituted and inspect for cloudiness before use.
Research use only. Not for human or veterinary use, not for use in diagnostic procedures, and not evaluated by the U.S. Food and Drug Administration.
